Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Top Cited Papers
Open Access
- 24 June 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 14 (7), 455-467
- https://doi.org/10.1038/nrc3760
Abstract
No abstract availableKeywords
This publication has 124 references indexed in Scilit:
- A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic InterventionCancer Cell, 2013
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung CarcinomaCancer Cell, 2011
- RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade SignalingCurrent Biology, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- V600E Braf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16
INK4a
EMBO Molecular Medicine, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Functional Proteomics Identifies Targets of Phosphorylation by B-Raf Signaling in MelanomaMolecular Cell, 2009
- Mutations of the BRAF gene in human cancerNature, 2002